Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma
JJ Urquijo-Ponce, C Alventosa-Mateu… - World Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is a high mortality neoplasm which usually appears on a
cirrhotic liver. The therapeutic arsenal and subsequent prognostic outlook are intrinsically …
cirrhotic liver. The therapeutic arsenal and subsequent prognostic outlook are intrinsically …
[HTML][HTML] The omics technologies and liquid biopsies: Advantages, limitations, applications
Over the last few years, the development of so-called omics technologies has greatly
contributed to the discovery of new biomarkers and targets, embracing various fields from …
contributed to the discovery of new biomarkers and targets, embracing various fields from …
Microfluidic biosensors for biomarker detection in body fluids: a key approach for early cancer diagnosis
Early detection of cancer significantly improves patient outcomes, with biomarkers offering a
promising avenue for earlier and more precise diagnoses. Microfluidic biosensors have …
promising avenue for earlier and more precise diagnoses. Microfluidic biosensors have …
Deep learning-based multimodal spatial transcriptomics analysis for cancer
The advent of deep learning (DL) and multimodal spatial transcriptomics (ST) has
revolutionized cancer research, offering unprecedented insights into tumor biology. This …
revolutionized cancer research, offering unprecedented insights into tumor biology. This …
Treatment options for advanced hepatocellular carcinoma: the potential of biologics
Introduction Advanced hepatocellular carcinoma (HCC) represents a significant global
health burden, whose treatment has been recently revolutionized by the advent of biologic …
health burden, whose treatment has been recently revolutionized by the advent of biologic …
[PDF][PDF] Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination
immunotherapy response Authors Hiro Page 1 Transcriptomic signature in advanced …
immunotherapy response Authors Hiro Page 1 Transcriptomic signature in advanced …
ALKBH5 acts a tumor-suppressive biomarker and is associated with immunotherapy response in hepatocellular carcinoma
As immune-checkpoint inhibitors (ICIs) therapy has made great strides in hepatocellular
carcinoma (HCC) treatment, improving patient response to this strategy has become the …
carcinoma (HCC) treatment, improving patient response to this strategy has become the …
Breaking the Barriers of Therapy Resistance: Harnessing Ferroptosis for Effective Hepatocellular Carcinoma Therapy
X Lv, G Lan, L Zhu, Q Guo - Journal of Hepatocellular Carcinoma, 2024 - Taylor & Francis
Ferroptosis is a type of cell death that relies on iron and is distinguished by the occurrence of
lipid peroxidation and the buildup of reactive oxygen species. Ferroptosis has been …
lipid peroxidation and the buildup of reactive oxygen species. Ferroptosis has been …
Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma
Z Zheng, R Guan, R Zhao, J Gan, X **ong… - Frontiers in …, 2025 - frontiersin.org
Purpose The α-FAtE score, composed of alpha-fetoprotein, alkaline phosphatase, and
eosinophil levels, has been reported as a predictor of prognosis in hepatocellular carcinoma …
eosinophil levels, has been reported as a predictor of prognosis in hepatocellular carcinoma …
[HTML][HTML] Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications
A shift toward a T cell exhaustion phenotype is associated with the upregulation of
expression of programmed cell death protein 1 (PD-1) on T lymphocytes in patients with …
expression of programmed cell death protein 1 (PD-1) on T lymphocytes in patients with …